ISRCTN22073647已完成不适用
EUROACTION PLUS intensive smoking intervention: a randomised controlled trial of a smoking cessation programme with varenicline versus usual care
Imperial College London (UK)0 个研究点目标入组 1,060 人开始时间: 2010年1月21日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,060
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Vascular patients and partners:
- •1. Patients with a medical diagnosis of coronary or other atherosclerotic disease:
- •1.1. Acute myocardial infarction (ST segment elevation myocardial infarction [STEMI] or non-ST segment elevation myocardial infarction [NSTEMI])
- •1.2. Unstable angina
- •1.3. Stable angina pectoris
- •1.4. Elective revascularisation: coronary artery bypass graft (CABG), percutaneous transluminal angioplasty (PTCA)
- •1.5. Stroke
- •1.6. Transient ischaemic attack (TIA)
- •1.7. Peripheral vascular disease (PVD)
- •2. Have been smoking 5 or more cigarettes per day within the last month
- •3. Willing to make a quit attempt
- •4. Aged 18 years of age or older, but less than 80 years, either sex
- •The partners of all recruited coronary patients will also be identified and invited to participate in the preventive cardiology programme. Those who are smoking will also be offered the same smoking cessation service including varenicline.
- •High-risk people and partners:
- •1. Have been smoking 5 or more cigarettes per day within the last month
- •2. Willing to make a quit attempt
- •3. Men and women, 50 years of age or older, but less than 80 years, either sex
- •4. Either:
- •4.1. Newly identified high multifactorial risk individuals: CVD risk equal or greater than 5% over 10 years (now or projected to age 60 years), according to the HeartScore risk estimation system; or
- •4.2. Have been treated with antihypertensive and/or lipid-lowering therapies; or
- •4.3. Have diabetes mellitus
- •The partners of all recruited high risk patients will also be identified and invited to participate in the preventive cardiology programme. Those who are smoking will also be offered the same smoking cessation service including varenicline.
排除标准
- •Vascular patients:
- •1. Severe heart failure
- •2. Severe physical disability
- •3. Impaired cognitive function
- •4. Patients with acute coronary syndromes, with or without revasularisation, will not be included in the study until 2 weeks has elapsed following their coronary event
- •5. Hypersensitivity to varenicline (active substance or to any of the inactive ingredients)
- •6. History of suicidal attempt
- •7. History of psychosis
- •8. Bipolar disorders
- •9. Panic disorders
- •10. Epilepsy
- •11. History of alcohol dependence
- •High-risk people:
- •1. History of coronary or other atherosclerotic disease
- •2. Severe heart failure
- •3. Severe physical disability
- •4. Impaired cognitive function
- •5. Hypersensitivity to varenicline (active substance or to any of the inactive ingredients)
- •6. History of suicidal attempt within the last 10 years
- •7. History of psychosis
- •8. Bipolar disorders
- •9. Panic disorders
- •10. Epilepsy
- •11. History of alcohol dependence
研究者
相似试验
已完成
4 期
Euroaction plus intensive smoking intervention (varenicline)prevention of cardiovascular diseasesmoking cessation1008220610003216NL-OMON38232Clinical Research Governance Office,Sir Alexander Fleming Building, Imperial College212
进行中（未招募）
不适用
EUROACTION PLUS: Intensive smoking intervention (Varenicline) during a preventive cardiology programme for patients with established atherosclerotic disease, people at high cariovascular risk and their families - EUROACTION PLUS INTENSIVE SMOKING INTERVENTION (VARENICLINE)EUCTR2009-012451-18-NLImperial College London1,060
进行中（未招募）
不适用
EUROACTION PLUS: Intensive smoking intervention (Varenicline) during a preventive cardiology programme for patients with established atherosclerotic disease, people at high cariovascular risk and their families - EUROACTION PLUS INTENSIVE SMOKING INTERVENTION (VARENICLINE)Current cigarette smokers with coronary or other atherosclerotic disease or people at high risk of developing cardiovascular diseaseLevel: LLTClassification code 10053325Term: Smoking cessation therapyEUCTR2009-012451-18-GBImperial College London1,060
进行中（未招募）
1 期
EUROACTION PLUS con intervención intensiva sobre el tabaco (vareniclina) durante un programa de cardiología preventiva para pacientes con enfermedad aterosclerosa establecida, individuos con alto riesgo cardiovascular y sus familias - EUROACTION PLUS CON INTERVENCIÓN INTENSIVA SOBRE EL TABACO (VARENICLINA)Pacientes fumadores con enfermedad cardiovascular u otra enfermedad aterosclerosa o individuos con riesgo elevado de padecer ECVMedDRA version: 12.1Level: LLTClassification code 10053325Term: Smoking cessation therapyEUCTR2009-012451-18-ESImperial College London696
已完成
不适用
European drug addiction prevention trialISRCTN18092805Piedmont Centre for Drug Addiction Epidemiology (OED) (Italy)6,600